25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study

Yoshihara, Takeo; Horimoto, Masayoshi; Kitamura, Tetsuhisa; Osugi, Naoto; Ikezoe, Tatsuro; Kotani, Kaori; Sanada, Toru; Higashi, Churi; Yamaguchi, Daisuke; Ota, Makiyo; Mizuno, Tatsunori; Gotoh, Yasukazu; Okuda, Yorihide; Suzuki, Kunio

doi:https://doi.org/10.1136/bmjopen-2014-006950

25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study

Yoshihara, Takeo; Horimoto, Masayoshi; Kitamura, Tetsuhisa et al.

BMJ Open, 2015, 5(3), e006950

Number of Access:1,235（2025-10-22 17:52 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/78410

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
BMJOpen_05_03_006950	pdf	None	578 KB	101	2021.02.02

Creative Commons : Attribution - NonCommercial

Item Information

Output File Export EndNote Basic Export Mendeley

Title	25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study
Creator	NRID 1000020814601 1000020814601 researchmap permalink ty_gh ty_gh CreatorName Yoshihara, Takeo
	CreatorName Horimoto, Masayoshi
	NRID 1000030639810 1000030639810 ORCID 0000-0003-0107-0580 0000-0003-0107-0580 researchmap permalink Kitamura_T Kitamura_T Scopus Author ID 22234282700 22234282700 CreatorName Kitamura, Tetsuhisa
	CreatorName Osugi, Naoto
	CreatorName Ikezoe, Tatsuro
	CreatorName Kotani, Kaori
	CreatorName Sanada, Toru
	CreatorName Higashi, Churi
	CreatorName Yamaguchi, Daisuke
	CreatorName Ota, Makiyo
	CreatorName Mizuno, Tatsunori
	CreatorName Gotoh, Yasukazu
	CreatorName Okuda, Yorihide
	CreatorName Suzuki, Kunio
Description	Yoshihara T, Horimoto M, Kitamura T, et al. 25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study. BMJ Open 2015;5:e006950. doi: 10.1136/bmjopen-2014-006950
Abstract	Objectives: The aim of the present study was to assess the appropriate administration dose of non-steroidal anti-inflammation drugs to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). Importantly, the 100 mg dose of diclofenac recommended in Western countries has not been permitted in Japan. Design: A retrospective study. Settings: A single centre in Japan. Participants: This study enrolled patients who underwent ERCP at the Department of Gastroenterology, Osaka Saiseikai Senri Hospital, from April 2011 through June 2013, and who received either a 25 or a 50 mg dose of rectal diclofenac after ERCP. Primary outcome measure: The occurrence of post-ERCP pancreatitis (PEP). A multivariate regression model was used to assess the effect of the 50 mg dose (the 50 mg group) of rectal diclofenac and to compare it to the occurrence of PEP referring to the 25 mg group. Results: A total of 155 eligible patients received either 25 mg (84 patients) or 50 mg (71 patients) doses of rectal diclofenac after ERCP to prevent PEP. The proportion of PEP was significantly lower in the 50 mg group than in the 25 mg group (15.5% (11/71) vs 33.3% (28/84), p=0.018). In a multivariate analysis, the occurrence of PEP was significantly lower in the 50 mg group than in the 25 mg group even after adjusting potential confounding factors (adjusted OR=0.27, 95% CI 0.11 to 0.70). Conclusions: From this observation, the occurrence of PEP was significantly lower among ERCP patients with the 50 mg dose of rectal diclofenac than among those with the 25 mg dose.
Publisher	BMJ Publishing Group
Source Title	BMJ Open
Volume (Issue)	5(3)
Page	e006950
Date of Issued	2015-03-20
Language	English
Handle URL	https://hdl.handle.net/11094/78410
eISSN	20446055
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1136/bmjopen-2014-006950
Relation.isIdenticalTo	PMID 25795692
Access Rights	open access
CopyRight	© 2015 BMJ Publishing Group Ltd. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	BMJ Open. 2015, 5(3), p. e006950
DC.title	25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study
DC.creator	Yoshihara, Takeo
	Horimoto, Masayoshi
	Kitamura, Tetsuhisa
	Osugi, Naoto
	Ikezoe, Tatsuro
	Kotani, Kaori
	Sanada, Toru
	Higashi, Churi
	Yamaguchi, Daisuke
	Ota, Makiyo
	Mizuno, Tatsunori
	Gotoh, Yasukazu
	Okuda, Yorihide
	Suzuki, Kunio
DC.publisher	BMJ Publishing Group
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2015-03-20
DC.identifier	https://doi.org/10.1136/bmjopen-2014-006950
DC.description	Yoshihara T, Horimoto M, Kitamura T, et al. 25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study. BMJ Open 2015;5:e006950. doi: 10.1136/bmjopen-2014-006950
DCTERMS.abstract	Objectives: The aim of the present study was to assess the appropriate administration dose of non-steroidal anti-inflammation drugs to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). Importantly, the 100 mg dose of diclofenac recommended in Western countries has not been permitted in Japan. Design: A retrospective study. Settings: A single centre in Japan. Participants: This study enrolled patients who underwent ERCP at the Department of Gastroenterology, Osaka Saiseikai Senri Hospital, from April 2011 through June 2013, and who received either a 25 or a 50 mg dose of rectal diclofenac after ERCP. Primary outcome measure: The occurrence of post-ERCP pancreatitis (PEP). A multivariate regression model was used to assess the effect of the 50 mg dose (the 50 mg group) of rectal diclofenac and to compare it to the occurrence of PEP referring to the 25 mg group. Results: A total of 155 eligible patients received either 25 mg (84 patients) or 50 mg (71 patients) doses of rectal diclofenac after ERCP to prevent PEP. The proportion of PEP was significantly lower in the 50 mg group than in the 25 mg group (15.5% (11/71) vs 33.3% (28/84), p=0.018). In a multivariate analysis, the occurrence of PEP was significantly lower in the 50 mg group than in the 25 mg group even after adjusting potential confounding factors (adjusted OR=0.27, 95% CI 0.11 to 0.70). Conclusions: From this observation, the occurrence of PEP was significantly lower among ERCP patients with the 50 mg dose of rectal diclofenac than among those with the 25 mg dose.
DC.rights	© 2015 BMJ Publishing Group Ltd. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	78410
citation_title	25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study
citation_author	Yoshihara, Takeo
	Horimoto, Masayoshi
	Kitamura, Tetsuhisa
	Osugi, Naoto
	Ikezoe, Tatsuro
	Kotani, Kaori
	Sanada, Toru
	Higashi, Churi
	Yamaguchi, Daisuke
	Ota, Makiyo
	Mizuno, Tatsunori
	Gotoh, Yasukazu
	Okuda, Yorihide
	Suzuki, Kunio
citation_publisher	BMJ Publishing Group
citation_language	English
citation_date	2015-03-20
citation_journal_title	BMJ Open
citation_volume	5
citation_issue	3
citation_firstpage	e006950
citation_doi	https://doi.org/10.1136/bmjopen-2014-006950
citation_pmid	25795692
citation_public_url	https://hdl.handle.net/11094/78410

25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: A retrospective study

Link to primary information

Item Information

Show details